Q2039 HCPCS Level II code: Influenza virus vaccine, not otherwise specified
Q2039 is the HCPCS code for “Influenza virus vaccine, not otherwise specified” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q2039Influenza virus vaccine, not otherwise specified
Short description: Influenza virus vaccine, nos
HCPCS · United States
Medicare details
The indicators CMS publishes with Q2039 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Vaccinations
- Type of service
- Pneumococcal/flu vaccine
- BETOS category
- Immunizations/Vaccinations
- Added
- Jan 1, 2011
Where Q2039 sits
- 1Q codesTemporary codes
- 2Active code Q2039Influenza virus vaccine, not otherwise specified
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q2039 mean?
Q2039 is the HCPCS code for “Influenza virus vaccine, not otherwise specified” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q2039?
CMS lists Q2039’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Vaccinations”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q2039
All Q codesQ2028Injection, sculptra, 0.5 mgQ2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)Q2037Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)Q2038Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)Q2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusionQ2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusionQ2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mgQ2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg